WEE1 is a validated target of the microRNA miR-17-92 cluster in leukemia.

Cancer Genetics
Sonia Brockway, Nancy J Zeleznik-Le

Abstract

MicroRNAs are short single-stranded RNAs that regulate target gene expression by binding to complementary sites in the 3' untranslated region (UTR) of their mRNA targets. The polycistronic miR-17-92 cluster, which encodes miR-17, miR-18a, miR-19a, miR-20a, miR-19b, and miR-92a, was previously shown to be overexpressed in multiple types of cancer. In this study, target gene prediction algorithms were used to predict potential targets of the miR-17-92 cluster. WEE1, a kinase that inhibits cell cycle progression, was identified as a possible target of five of the six miRNAs in the cluster. Luciferase reporter assays were used to determine that miR-17, miR-20a, and miR-18a specifically target nucleotides 465-487 of the 3' UTR of WEE1, whereas miR-19a and miR-19b exert control on WEE1 by targeting nucleotides 1069-1091. A negative correlation was determined between endogenous miR-17 or miR-19a expression and endogenous WEE1 protein expression in the same panel of cell lines. We conclude that WEE1 is a valid target of the miR-17-92 cluster in leukemia.

References

May 14, 1996·Proceedings of the National Academy of Sciences of the United States of America·M H DreylingS K Bohlander
Nov 24, 2001·Trends in Cell Biology·P H O'Farrell
Feb 16, 2002·Methods : a Companion to Methods in Enzymology·K J Livak, T D Schmittgen
Aug 3, 2002·Science·György Hutvágner, Phillip D Zamore
Aug 7, 2003·Proceedings of the National Academy of Sciences of the United States of America·Yan ZengBryan R Cullen
Dec 31, 2003·Cell·Benjamin P LewisChristopher B Burge
Jun 10, 2005·Nature·Lin HeScott M Hammond
Jun 10, 2005·Nature·Kathryn A O'DonnellJoshua T Mendell
Feb 8, 2006·Proceedings of the National Academy of Sciences of the United States of America·Stefano VoliniaCarlo M Croce
Aug 1, 2006·Nature Genetics·Michael DewsAndrei Thomas-Tikhonenko
Jan 24, 2008·Molecular and Cellular Biology·Irena IvanovskaMichele A Cleary
Oct 4, 2008·Proceedings of the National Academy of Sciences of the United States of America·Zejuan LiJianjun Chen
Jan 30, 2010·Methods : a Companion to Methods in Enzymology·Vladimir Benes, Mirco Castoldi
Feb 6, 2010·Proceedings of the National Academy of Sciences of the United States of America·Shuangli MiJianjun Chen

❮ Previous
Next ❯

Citations

Dec 5, 2015·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Xin YuWilliam Ka Kei Wu
Dec 5, 2015·Journal of Diabetes Research·Celestino SarduRaffaele Marfella
Apr 22, 2017·Journal of Neuropathology and Experimental Neurology·Heather AmesFausto J Rodriguez
Aug 4, 2018·Journal of Cellular and Molecular Medicine·Weihan WangZhifan Jia
Jun 15, 2018·Indian Journal of Dental Research : Official Publication of Indian Society for Dental Research·Soussan Irani, Bahar Jafari
Jun 21, 2019·Circulation Research·Jessica R Hoffman, Michael E Davis
May 26, 2018·Biological Reviews of the Cambridge Philosophical Society·Shama P KabekkoduKapaettu Satyamoorthy
Sep 5, 2020·Reports of Practical Oncology and Radiotherapy : Journal of Greatpoland Cancer Center in Poznań and Polish Society of Radiation Oncology·Tomasz KolendaKatarzyna Lamperska
May 1, 2021·Biomedicines·Lola Llobat, Olivia Gourbault

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.